Corcept Therapeutics develops and researches cortisol modulators, which are critical molecules that regulate cortisol activity at the glucocorticoid receptor. Since obtaining FDA approval for Korlym® (mifepristone) in 2012—marking the first treatment for hypercortisolism—Corcept has continued its commitment to exploring cortisol modulation across a variety of serious conditions, including those in endocrinology, oncology, metabolism, and neurology. With over 30 ongoing clinical studies, the organization is focused on discovering novel therapies to address significant unmet medical needs. Corcept emphasizes collaboration, scientific rigor, and a patient-centric approach, striving to make impactful advancements in the understanding and treatment of diseases related to cortisol imbalances. The company fosters a work environment that champions commitment to both innovation and the well-being of patients.